patients with chronic ITP who do not respond to or cannot tolerate TPO-RA drugs are treated with rituximab or mycophenolate. While there is no direct comparison between Tavlesse and these agents ...
The addition of brentuximab vedotin to lenalidomide and rituximab improved survival ... in each treatment arm developed neutropenia, thrombocytopenia, diarrhea or anemia. Researchers acknowledged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback